Omicron variant: Brazilian health regulator requests further data on impact of authorized vaccines

The request was sent to Pfizer, the Butantan Institute, the Oswaldo Cruz Foundation (Fiocruz) and Janssen.

RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (ANVISA) on Wednesday, December 1, announced that it has requested the developers of Covid-19 vaccines authorized in Brazil to provide data on ongoing studies related to the new Omicron variant.

"Anvisa requests that developers of authorized vaccines should monitor and assess the impact of variants on the efficacy and effectiveness of immunizers. However, it should be noted that these studies require time, since genetic information and patient samples must be obtained in order to conduct the tests and analysis," the agency said.

The companies developing immunizers will conduct performance tests . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?